Jim Reddoch

EVP Investments & Chief Scientific Officer
Royalty Pharma

Dr. Reddoch joined Royalty Pharma in 2008 as Executive Vice President and Head of Research. He is now Executive Vice President, Investments and Chief Scientific Officer, the group that sources and analyzes new investment opportunities and partnerships. In 2020, he started the Strategy & Analytics department to use large data sources more effectively in the firm’s analyses and sourcing. Prior to joining Royalty Pharma, Dr. Reddoch was Head of Healthcare Research at FBR Capital Markets. Previously, Dr. Reddoch was a biotechnology analyst at Bank of America and CIBC World Markets. Dr. Reddoch serves on the board of Avillion, a London-based drug development company, and on Memorial Sloan Kettering Cancer Center’s external review board for its Technology Development Fund. He is Vice Chairman of the Therapy Acceleration Program at the Leukemia & Lymphoma Society. Dr. Reddoch has a BA from Furman University, a PhD in biochemistry and molecular genetics from the University of Alabama and was a postdoctoral fellow at Yale University.